Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: April 06, 2026
Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action.
Journal: The American journal of psychiatry
Published: November 19, 2025
Keep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophrenia.
Journal: Schizophrenia research. Cognition
Published: October 30, 2025
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial.
Journal: Journal of psychiatric research
Published: June 25, 2025
Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia.
Journal: The Journal of clinical psychiatry
Published: June 09, 2025
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.
Journal: medRxiv : the preprint server for health sciences
Published: May 05, 2025
Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study.
Journal: Schizophrenia (Heidelberg, Germany)
Published: March 14, 2025
Assessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative study.
Journal: Schizophrenia (Heidelberg, Germany)
Published: January 08, 2025
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research.
Journal: Pharmaceutical medicine
Published: December 12, 2024
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry.
Journal: Advances in neurobiology
Published: November 19, 2024
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Journal: Biological psychiatry
Published: July 16, 2024
Last Updated: 09/26/2026